Published Online
on February 7, 2008

A more recent version of this article appeared on April 1, 2008

This Article Free upon publication Full Text (PDF) Data Supplement All Versions of this Article: 51/4/1103    most recent HYPERTENSIONAHA.107.105296v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Os, I. Articles by Oparil, S. Search for Related Content PubMed PubMed Citation Articles by Os, I. Articles by Oparil, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATENOLOL LOSARTAN POTASSIUM Medline Plus Health Information Blood Pressure Medicines High Blood Pressure Related Collections Hypertrophy Clinical Studies

Submitted on November 19, 2007
Revised on December 12, 2007

Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy. Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study

Ingrid Os^*; Veronica Franco; Sverre E. Kjeldsen; Karin Manhem; Richard B. Devereux; Eva Gerdts; Darcy A. Hille; Paulette A. Lyle; Peter M. Okin; Björn Dahlöf; and Suzanne Oparil

From the Department of Nephrology (I.O., S.E.K.), Ullevaal University Hospital, Oslo, Norway; University of Oslo (I.O.), Oslo, Norway; Ohio State University (V.F.), Columbus; University of Alabama at Birmingham (S.O.); University of Michigan (S.E.K.), Ann Arbor; Sahlgrenska University Hospital/Östra (K.M., B.D.), Gothenburg, Sweden; Weill Cornell Medical College (R.B.D., P.M.O.), New York, NY; Institute of Medicine (E.G.), University of Bergen, Bergen, Norway; Department of Heart Disease (E.G.), Haukeland University Hospital, Bergen, Norway; and Merck Research Laboratories (D.A.H., P.A.L.), Upper Gwynedd, Pa.

^* To whom correspondence should be addressed. E-mail: ingrid.os{at}medisin.uio.no.

Abstract—Hypertension is a risk factor for cardiovascular disease and outcomes in women. These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women. Fewer events occurred in women versus men. Women in the losartan group had significant reductions in the primary end point (215 [18.2 per 1000 patient-years] versus 261 [22.5 per 1000 patient-years]; hazard ratio [HR]: 0.82 [95% CI: 0.68 to 0.98]; P=0.031), stroke (109 versus 154; HR: 0.71 [95% CI: 0.55 to 0.90]; P=0.005), total mortality (HR: 0.77 [95% CI: 0.63 to 0.95]; P=0.014), and new-onset diabetes (HR: 0.75 [95% CI: 0.59 to 0.94]; P=0.015) versus the atenolol group, with no between-treatment difference for myocardial infarction (HR: 1.02 [95% CI: 0.74 to 1.39]; P=0.925), cardiovascular mortality (HR: 0.86 [95% CI: 0.64 to 1.14]; P=0.282), or hospitalization for heart failure (HR: 0.94 [95% CI: 0.68 to 1.28]; P=0.677). More women in the losartan group required hospitalization for angina (HR: 1.70 [95% CI: 1.16 to 2.51]; P=0.007). Risk reductions for the primary composite end point, stroke, total mortality, and new-onset diabetes were significantly greater with losartan- versus atenolol-based treatment in women with hypertension and left ventricular hypertrophy in the LIFE study. The risk reductions for losartan, along with the tests for the interaction of treatment and gender, indicated that the treatment effect was consistent in men and women for all of the end points tested, with the exception of hospitalization for angina.

Key words: gender • hypertension • left ventricular hypertrophy • outcomes

This article has been cited by other articles:

				N. Reichek, R. B. Devereux, R. A. Rocha, R. Hilkert, D. Hall, D. Purkayastha, and B. Pitt Magnetic Resonance Imaging Left Ventricular Mass Reduction With Fixed-Dose Angiotensin-Converting Enzyme Inhibitor-Based Regimens in Patients With High-Risk Hypertension Hypertension, October 1, 2009; 54(4): 731 - 737. [Abstract] [Full Text] [PDF]

				D. J. Campbell Can the Study of Female Rats Help Our Understanding of Women? Hypertension, December 1, 2008; 52(6): e142 - e142. [Full Text] [PDF]

				A. K. Sampson, K. M. Moritz, E. S. Jones, R. E. Widdop, and K. M. Denton Response to Can the Study of Female Rats Help Our Understanding of Women? Hypertension, December 1, 2008; 52(6): e143 - e143. [Full Text] [PDF]

				E. Agabiti-Rosei and M. Salvetti Gender Differences in the Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy Hypertension, July 1, 2008; 52(1): 59 - 60. [Full Text] [PDF]

				C. Escobar and V. Barrios Gender Differences in Left Ventricular Hypertrophy Regression Hypertension, June 1, 2008; 51(6): e58 - e58. [Full Text] [PDF]

				I. Os, R. B. Devereux, and P. M. Okin Response to Gender Differences in Left Ventricular Hypertrophy Regression Hypertension, June 1, 2008; 51(6): e59 - e59. [Full Text] [PDF]